Celia Oreja-Guevara
Universidad Complutense de Madrid
H-index: 51
Europe-Spain
Top articles of Celia Oreja-Guevara
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing … | Journal of the Neurological Sciences | Sean Pittock Michael Barnett Jeffrey Bennett Achim Berthele Jérôme De Sèze | 2023/12/1 |
Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023 | Neurología | JE Meca-Lallana S Martínez Yélamos S Eichau MA Llaneza J Martín Martínez | 2024/3/1 |
Multiple Sclerosis Treatment and Holistic Patient Care Consensus by the Spanish Society of Neurology (P3-6.013) | José E Meca Lallana Sergio Martínez Yélamos Sara Eichau Madueno Miguel Ángel Llaneza Jesús Martín Martínez | 2024/4/14 | |
Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis | Frontiers in Oncology | Virginia Arrazubi Gerardo Cajaraville David Cantero Jordi Giralt Ricard Mesia | 2022/1/24 |
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023 | Neurología (English Edition) | JE Meca-Lallana S Martínez Yélamos S Eichau MÁ Llaneza J Martín Martínez | 2024/1/16 |
Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date | Presented at the 76th Annual Meeting of the American Academy of Neurology (AAN); April | R Bove C Pietrasanta C Oreja-Guevara K Hellwig R Dobson | 2024/4/9 |
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies | Journal of neurology | Ying Li Alice Saul Bruce Taylor Anne-Louise Ponsonby Steve Simpson-Yap | 2024/1 |
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom | Journal of medical economics | T Spelman WL Herring C Acosta R Hyde VG Jokubaitis | 2024/12/31 |
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review | Óscar Fernández Per Soelberg Sörensen Giancarlo Comi Patrick Vermersch Hans-Peter Hartung | 2024/4/5 | |
The European Academy of Neurology N euro COVID‐19 Task Force: A lesson for the future | European journal of neurology | Francesco Cavallieri Johann Sellner Tamar Akhvlediani Claudio L Bassetti Daniel Bereczki | 2024/4/26 |
Données de grossesses et des enfants de femmes recevant ocrelizumab pour le traitement de la sclérose en plaques: analyse de la plus grande base de données disponible | Revue Neurologique | Celia Oreja-Guevara Sandra Vukusic Carlo Pietrasanta Thomas Frederick Mcelrath Kerstin Hellwig | 2023/4/1 |
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database | Multiple Sclerosis and Related Disorders | Kerstin Hellwig Celia Oreja-Guevara Sandra Vukusic Carlo Pietrasanta Thomas Mcelrath | 2023/12/1 |
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience | Frontiers in Neurology | Francisco Gascón-Giménez Carmen Alcalá Lluís Ramió-Torrentà Paloma Montero Jorge Matías-Guiu | 2023/3/7 |
Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: a comparative study | Multiple Sclerosis and Related Disorders | Luis A Rodriguez de Antonio Ines Cuberta-Gonzalez Inmaculada Garcia-Castañon Celia Oreja-Guevara | 2023/1/1 |
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive | Reassessing the immune system contribution in multiple sclerosis: Therapeutic target, biomarkers of disease and immune pathogenesis | JI Fernandez-Velasco E Monreal J Kuhle V Meca-Lallana J Meca-Lallana | 2023/4/10 |
Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis | JAMA neurology | Tomas Kalincik Sifat Sharmin Izanne Roos Mark S Freedman Harold Atkins | 2023/7/1 |
Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS)(ConPlanEM Study): Delphi Consensus Statements | Cureus | Celia Oreja-Guevara Mar Tintoré Virginia Meca José María Prieto José Meca | 2023/8/24 |
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple … | Celia Oreja-Guevara Stanca Potra Birgit Bauer Diego Centonze Maria-Paz Giambastiani | 2023/12 | |
Predictors of treatment switching in the big multiple sclerosis data network | Frontiers in Neurology | Tim Spelman Melinda Magyari Helmut Butzkueven Anneke Van Der Walt Sandra Vukusic | 2023/12/22 |
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets | Klaus Schmierer Heinz Wiendl Celia Oreja-Guevara Diego Centonze Anita Chudecka | 2023/2 |
